Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20525995 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
Condition: Myeloid Leukemia, Chronic
Interventions: Drug: Dasatinib;   Drug: Imatinib

Indicates status has not been verified in more than two years